• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

日本原发性肝癌第19次随访调查报告。

Report of the 19th follow-up survey of primary liver cancer in Japan.

作者信息

Kudo Masatoshi, Izumi Namiki, Ichida Takafumi, Ku Yonson, Kokudo Norihiro, Sakamoto Michiie, Takayama Tadatoshi, Nakashima Osamu, Matsui Osamu, Matsuyama Yutaka

机构信息

The Liver Cancer Study Group of Japan, c/o Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

出版信息

Hepatol Res. 2016 Mar;46(5):372-90. doi: 10.1111/hepr.12697.

DOI:10.1111/hepr.12697
PMID:26970231
Abstract

The 19th Nationwide Follow-up Survey of Primary Liver Cancer in Japan comprised 20 850 primary liver cancer patients newly registered at 482 medical institutions over a period of 2 years (from 1 January 2006 to 31 December 2007). Of these, 94.7% had hepatocellular carcinoma (HCC) and 4.4% had intrahepatic cholangiocarcinoma (ICC). In addition, follow-up data were obtained regarding 34 752 patients who were registered in the previous survey. Epidemiological and clinicopathological factors, diagnosis, and treatment were examined in newly registered patients. Compared with the 18th follow-up survey, the present follow-up survey suggested an increase in the number of elderly and female patients, a reduction in the number of hepatitis B surface antigen- and anti-hepatitis C virus antibody-positive patients, and a reduction in tumor size at the time of clinical diagnosis. In terms of local ablation therapy, the number of patients receiving radiofrequency ablation therapy increased. The cumulative survival rates for newly registered patients between 1996 and 2007 were calculated for each histological type (HCC, ICC, and combined HCC and ICC) and stratified according to background factors and treatments. The cumulative survival rates of newly registered patients between 1978 and 2007 were calculated after dividing individuals into groups according to registration date (1978-1987, 1988-1997, and 1998-2007). The data obtained from this follow-up survey will contribute to the medical management of primary liver cancer and facilitate future research.

摘要

日本第19次全国原发性肝癌随访调查涵盖了在2年时间内(从2006年1月1日至2007年12月31日)于482家医疗机构新登记的20850例原发性肝癌患者。其中,94.7%为肝细胞癌(HCC),4.4%为肝内胆管癌(ICC)。此外,还获取了之前调查中登记的34752例患者的随访数据。对新登记患者的流行病学和临床病理因素、诊断及治疗情况进行了检查。与第18次随访调查相比,本次随访调查显示老年患者和女性患者数量增加,乙肝表面抗原和抗丙型肝炎病毒抗体阳性患者数量减少,临床诊断时肿瘤大小减小。在局部消融治疗方面,接受射频消融治疗的患者数量增加。计算了1996年至2007年新登记患者按每种组织学类型(HCC、ICC以及HCC与ICC合并)的累积生存率,并根据背景因素和治疗方法进行分层。在根据登记日期(1978 - 1987年、1988 - 1997年和1998 - 2007年)将个体分组后,计算了1978年至2007年新登记患者的累积生存率。本次随访调查所获得的数据将有助于原发性肝癌的医疗管理,并促进未来的研究。

相似文献

1
Report of the 19th follow-up survey of primary liver cancer in Japan.日本原发性肝癌第19次随访调查报告。
Hepatol Res. 2016 Mar;46(5):372-90. doi: 10.1111/hepr.12697.
2
Report of the 18th follow-up survey of primary liver cancer in Japan.日本原发性肝癌第18次随访调查报告。
Hepatol Res. 2010 Nov;40(11):1043-1059. doi: 10.1111/j.1872-034X.2010.00731.x.
3
Report of the 17th Nationwide Follow-up Survey of Primary Liver Cancer in Japan.日本第 17 次原发性肝癌全国随访调查报告。
Hepatol Res. 2007 Sep;37(9):676-91. doi: 10.1111/j.1872-034X.2007.00119.x.
4
Report of the 22nd nationwide follow-up Survey of Primary Liver Cancer in Japan (2012-2013).日本第22次全国原发性肝癌随访调查(2012 - 2013年)报告
Hepatol Res. 2022 Jan;52(1):5-66. doi: 10.1111/hepr.13675. Epub 2022 Jan 2.
5
Report of the 16th follow-up survey of primary liver cancer.原发性肝癌第 16 次随访调查报告。
Hepatol Res. 2005 Jul;32(3):163-72. doi: 10.1016/j.hepres.2005.04.005. Epub 2005 Jul 18.
6
Report of the 21st Nationwide Follow-up Survey of Primary Liver Cancer in Japan (2010-2011).日本第21次全国原发性肝癌随访调查(2010 - 2011年)报告
Hepatol Res. 2021 Apr;51(4):355-405. doi: 10.1111/hepr.13612. Epub 2021 Mar 4.
7
Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan.日本第20次全国原发性肝癌随访调查结果报告。
Hepatol Res. 2020 Jan;50(1):15-46. doi: 10.1111/hepr.13438. Epub 2020 Jan 5.
8
Report of the 23rd nationwide follow-up survey of primary liver cancer in Japan (2014-2015).日本第23次全国原发性肝癌随访调查(2014 - 2015年)报告
Hepatol Res. 2023 Oct;53(10):895-959. doi: 10.1111/hepr.13953. Epub 2023 Sep 5.
9
Report of the 15th follow-up survey of primary liver cancer.原发性肝癌第15次随访调查报告。
Hepatol Res. 2004 Jan;28(1):21-29. doi: 10.1016/j.hepres.2003.08.002.
10
Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers.与其他肝癌相比,肝细胞癌-胆管细胞癌混合癌的临床和病理特征。
J Gastroenterol Hepatol. 2019 Jun;34(6):1074-1080. doi: 10.1111/jgh.14547. Epub 2018 Dec 16.

引用本文的文献

1
Carbon-Ion Radiotherapy for Hepatocellular Carcinoma: Current Status and Future Prospects: A Narrative Review.肝细胞癌的碳离子放疗:现状与未来展望:一篇叙述性综述
J Clin Med. 2025 Aug 29;14(17):6107. doi: 10.3390/jcm14176107.
2
Primary Prophylaxis for High-Risk Varices in Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombus Delayed Hepatic Decompensation: A Retrospective, Propensity Score Matching Study.肝细胞癌合并门静脉癌栓患者高危静脉曲张的一级预防延缓肝失代偿:一项回顾性倾向评分匹配研究
J Hepatocell Carcinoma. 2025 May 28;12:1057-1067. doi: 10.2147/JHC.S520318. eCollection 2025.
3
Transarterial chemoembolization versus hepatic arterial infusion chemotherapy as first treatment for hepatocellular carcinoma with macrovascular invasion.
经动脉化疗栓塞术与肝动脉灌注化疗作为伴有大血管侵犯的肝细胞癌的一线治疗方法比较
Int J Med Sci. 2025 Feb 24;22(6):1415-1424. doi: 10.7150/ijms.108144. eCollection 2025.
4
Phase II study with sorafenib plus radiotherapy for advanced HCC with portal and/or hepatic vein tumor thrombosis.索拉非尼联合放疗治疗伴有门静脉和/或肝静脉肿瘤血栓形成的晚期肝癌的II期研究。
JHEP Rep. 2024 Nov 28;7(3):101287. doi: 10.1016/j.jhepr.2024.101287. eCollection 2025 Mar.
5
GALAD, or des-gamma-carboxy prothrombin compared with alpha-foetoprotein for the diagnosis of hepatocellular carcinoma in people with chronic liver disease.GALAD(即去γ-羧基凝血酶原)与甲胎蛋白在慢性肝病患者肝细胞癌诊断中的比较。
Cochrane Database Syst Rev. 2024 Dec 17;12(12):CD015826. doi: 10.1002/14651858.CD015826.
6
Unusual location of metastatic lymph nodes of hepatocellular carcinoma in the mediastinum: Case report.肝细胞癌纵隔转移性淋巴结的不寻常部位:病例报告
Radiol Case Rep. 2024 Oct 25;20(1):285-288. doi: 10.1016/j.radcr.2024.10.027. eCollection 2025 Jan.
7
Prognostic factors in patients with intrahepatic cholangiocarcinoma.肝内胆管细胞癌患者的预后因素。
Sci Rep. 2024 Aug 17;14(1):19084. doi: 10.1038/s41598-024-70124-z.
8
Efficacy and safety of hepatic arterial infusion chemotherapy combined with tyrosine kinase inhibitors and immune checkpoint inhibitors in the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis in the main trunk.肝动脉灌注化疗联合酪氨酸激酶抑制剂和免疫检查点抑制剂治疗门静脉主干肿瘤血栓形成的晚期肝细胞癌的疗效和安全性
Front Oncol. 2024 Jul 15;14:1374149. doi: 10.3389/fonc.2024.1374149. eCollection 2024.
9
Cost-Effectiveness Comparison of Carbon-Ion Radiation Therapy and Transarterial Chemoembolization for Hepatocellular Carcinoma.碳离子放射治疗与经动脉化疗栓塞治疗肝细胞癌的成本效益比较
Adv Radiat Oncol. 2024 Jan 15;9(4):101441. doi: 10.1016/j.adro.2024.101441. eCollection 2024 Apr.
10
A comprehensive review of phytoconstituents in liver cancer prevention and treatment: targeting insights into molecular signaling pathways.肝癌防治中植物成分的综合述评:靶向分子信号通路的见解。
Med Oncol. 2024 May 4;41(6):134. doi: 10.1007/s12032-024-02333-5.